Cargando…
Antistaphylococcal evaluation of indole–naphthalene hybrid analogs
Resistance developments against established antibiotics are an emerging problem for antibacterial therapies. Infections with Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) have become more difficult to treat with standard antibiotics that often fail, especially against MRSA. In con...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331074/ https://www.ncbi.nlm.nih.gov/pubmed/30666089 http://dx.doi.org/10.2147/DDDT.S184965 |
_version_ | 1783387082301898752 |
---|---|
author | Ashraf, Kerolos Yasrebi, Kaveh Adeniyi, Emmanuel Tola Hertlein, Tobias Ohlsen, Knut Lalk, Michael Erdmann, Frank Hilgeroth, Andreas |
author_facet | Ashraf, Kerolos Yasrebi, Kaveh Adeniyi, Emmanuel Tola Hertlein, Tobias Ohlsen, Knut Lalk, Michael Erdmann, Frank Hilgeroth, Andreas |
author_sort | Ashraf, Kerolos |
collection | PubMed |
description | Resistance developments against established antibiotics are an emerging problem for antibacterial therapies. Infections with Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) have become more difficult to treat with standard antibiotics that often fail, especially against MRSA. In consequence, novel antibiotics are urgently needed. Antibiotics from natural sources own complicated structures that cause difficulties for a chemical synthetic production. We developed novel small-molecule antibacterials that are easily accessible in a simple one-pot synthesis. The central indolonaphthalene core is substituted with indole residues at various positions. Both the varied indole substitutions and their positions at the molecular scaffold influence the determined antibacterial activity against the evaluated Staphylococcus strains. Best activities have been found for 5-chloro, -cyano, and -hydroxyl indole substitutions. Therefore, first promising lead compounds could be identified that are nontoxic in human HEK and SH-SY5Y cells and exceed the activity of used standard antibiotics, especially against MRSA. |
format | Online Article Text |
id | pubmed-6331074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63310742019-01-21 Antistaphylococcal evaluation of indole–naphthalene hybrid analogs Ashraf, Kerolos Yasrebi, Kaveh Adeniyi, Emmanuel Tola Hertlein, Tobias Ohlsen, Knut Lalk, Michael Erdmann, Frank Hilgeroth, Andreas Drug Des Devel Ther Short Report Resistance developments against established antibiotics are an emerging problem for antibacterial therapies. Infections with Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) have become more difficult to treat with standard antibiotics that often fail, especially against MRSA. In consequence, novel antibiotics are urgently needed. Antibiotics from natural sources own complicated structures that cause difficulties for a chemical synthetic production. We developed novel small-molecule antibacterials that are easily accessible in a simple one-pot synthesis. The central indolonaphthalene core is substituted with indole residues at various positions. Both the varied indole substitutions and their positions at the molecular scaffold influence the determined antibacterial activity against the evaluated Staphylococcus strains. Best activities have been found for 5-chloro, -cyano, and -hydroxyl indole substitutions. Therefore, first promising lead compounds could be identified that are nontoxic in human HEK and SH-SY5Y cells and exceed the activity of used standard antibiotics, especially against MRSA. Dove Medical Press 2019-01-10 /pmc/articles/PMC6331074/ /pubmed/30666089 http://dx.doi.org/10.2147/DDDT.S184965 Text en © 2019 Ashraf et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Short Report Ashraf, Kerolos Yasrebi, Kaveh Adeniyi, Emmanuel Tola Hertlein, Tobias Ohlsen, Knut Lalk, Michael Erdmann, Frank Hilgeroth, Andreas Antistaphylococcal evaluation of indole–naphthalene hybrid analogs |
title | Antistaphylococcal evaluation of indole–naphthalene hybrid analogs |
title_full | Antistaphylococcal evaluation of indole–naphthalene hybrid analogs |
title_fullStr | Antistaphylococcal evaluation of indole–naphthalene hybrid analogs |
title_full_unstemmed | Antistaphylococcal evaluation of indole–naphthalene hybrid analogs |
title_short | Antistaphylococcal evaluation of indole–naphthalene hybrid analogs |
title_sort | antistaphylococcal evaluation of indole–naphthalene hybrid analogs |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331074/ https://www.ncbi.nlm.nih.gov/pubmed/30666089 http://dx.doi.org/10.2147/DDDT.S184965 |
work_keys_str_mv | AT ashrafkerolos antistaphylococcalevaluationofindolenaphthalenehybridanalogs AT yasrebikaveh antistaphylococcalevaluationofindolenaphthalenehybridanalogs AT adeniyiemmanueltola antistaphylococcalevaluationofindolenaphthalenehybridanalogs AT hertleintobias antistaphylococcalevaluationofindolenaphthalenehybridanalogs AT ohlsenknut antistaphylococcalevaluationofindolenaphthalenehybridanalogs AT lalkmichael antistaphylococcalevaluationofindolenaphthalenehybridanalogs AT erdmannfrank antistaphylococcalevaluationofindolenaphthalenehybridanalogs AT hilgerothandreas antistaphylococcalevaluationofindolenaphthalenehybridanalogs |